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Abstract
Background: Recently, topical dexamethasone-induced ocular hypertension and a consequent loss of retinal
ganglion cells (RGCs) have been described in mice. This has been proposed as a model of steroid-induced
glaucoma. In this study, we set up and evaluated a similar model in rats.
Results: Ten-week old Sprague Dawley (SD) rats (N = 12) were used to evaluate the effect of topical 0.1 %
dexamethasone (50 μl) administered 3 times daily for 4 weeks. Sodium chloride (0.9 %) was used in another group
of rats (N = 12) that served as the controls. After 1 week, we observed a progressive decrease in body weight in the
dexamethasone-treated rats compared both to the pre-treatment baseline and the vehicle-treated rats. In contrast
to earlier work that showed elevated Intraocular pressure (IOP) following dexamethasone instillation in mice, IOP in
the rats unexpectedly fell to 11.3 ± 1.3 mmHg in the treated eyes, compared to 14.8 ± 2.4 mmHg in the untreated
eyes, after 3 weeks of topical dexamethasone (P = 0.032). Blood tests performed after 4 weeks of treatment showed
a 3.3-fold increase in both plasma cholesterol (P < 0.001) and alanine transaminase (P = 0.019) in the
dexamethasone-treated rats compared to the control rats. Meanwhile, topical steroid did not induce changes in
either plasma blood glucose or glycated hemoglobin (HbA1c). We also did not detect changes in the expression of
RGC markers (with real-time PCR) following the treatment.
Conclusions: In contrast to mice, which previously showed increased IOP following the topical administration of
dexamethasone, the rats displayed a paradoxical reduction in IOP following a similar treatment. This was
accompanied by a loss of body weight without affecting the level of blood glucose.
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Background
Glaucoma is a common cause of visual impairment, af-
fecting about 70 million people worldwide [1, 2]. The
condition is characterized by a selective loss of the ret-
inal ganglion cells (RGCs) and their nerve fibers, result-
ing in a progressive narrowing of the visual field [3].
High intraocular pressure (IOP) is recognized as one of
the risk factors for glaucoma [4]. Available treatments
for glaucoma thus mostly rely on the pharmacological
and/or surgical reduction of IOP.
In the classical model of steroid action, steroid mole-
cules bind with steroid receptors and modulate tran-
scription of various genes [5, 6]. Glucocorticoid, which
is a class of steroid hormone, has anti-inflammatory ef-
fects, and is used in the clinical treatment of patients
with diseases such as autoimmune disorders, allergies,
and intraocular inflammation including uveitis and optic
neuritis [7–9]. On the other hand, glucocorticoid treat-
ment also has numbers of adverse effects, such as gain
of weight, increased blood glucose, triglyceride, and
cholesterol as well as elevated blood pressure [10, 11].
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Some cases of elevated IOP occur as the off-target result
of systemic or topical glucocorticoid therapy when pa-
tients are treated for various conditions unrelated to glau-
coma [12, 13]. If not diagnosed and treated promptly, this
IOP elevation can eventually induce a loss of RGCs and
result in the development of steroid-induced glaucoma.
This problem is not uncommon, as the topical administra-
tion of glucocorticoid, such as dexamethasone or beta-
methasone, can elevate IOP in approximately 30–40 % of
the general population [12–17]. However, the pathological
mechanisms of steroid-induced glaucoma are poorly
understood, because an animal model has not been avail-
able to emulate this condition. Recently, however, a model
of steroid-induced glaucoma accompanied by ocular
hypertension and a subsequent loss of RGCs was estab-
lished, in which topical treatment with dexamethasone
was used for 6 weeks in C57BL/6J mice [18]. Detailed ana-
lysis of this model revealed that endoplasmic reticulum
(ER) stress played a critical role in its pathology, suggest-
ing that the suppression of ER stress is a promising ap-
proach to treat steroid-induced glaucoma.
Research into the pathological mechanisms of ocular
disease can gain a few advantages by using rats rather
than mice. One of the clearest is that IOP can be reliably
measured in rats. Applying a tonometer to the center of
a mouse cornea, which measures ~ 3.5 mm in diameter,
is technically far more complicated and more prone to
variation than the same procedure in rats, which have a
substantially bigger cornea (~7.0 mm in diameter). An-
other advantage is that, in general, rats are more tolerant
of behavioral tests than mice. This is important, as in vivo
functional assessment of the RGCs is difficult, making
visually cued behavioral testing a particularly informative
way of evaluating the visual status of animals with RGC
loss.
In this study, we attempted to develop a model of
steroid-induced ocular hypertension and glaucoma in rats
by applying a treatment regimen similar to that reported
to induce this pathology in mice. Surprisingly, we found
that topical steroid administration reduced IOP in rats, a
result that was contradictory to previous findings in mice.
Methods
Animals
Ten-week-old male Sprague Dawley (SD) rats were ob-
tained from SLC (Shizuoka, Japan). All animals were
maintained and handled in accordance with the Associ-
ation for Research in Vision and Ophthalmology
(ARVO) Statement for Use of Animals in Ophthalmic
Vision Research and the Tohoku University Guidelines
for Animal Research. All experimental procedures were
conducted after approval by the ethics committee for
animal experiments at the Tohoku University Graduate
School of Medicine.
Treatment with topical ocular dexamethasone
Dexamethasone 21-phosphate disodium (Sigma, St. Louis,
Mo, USA) was dissolved in saline (Otsuka Pharmaceutical,
Japan) to make a 0.1 % solution. Sodium chloride (0.9 %;
saline) served as the vehicle control. Either dexametha-
sone or vehicle was applied topically to the right eyes
(50 μl/eye) of the rats (N = 12 per group) 3 times daily.
The amount of steroid used was calculated based on pre-
vious work performed with mice [18]. The initial plan to
administer the eye drops for 6 weeks was altered to
4 weeks following the unexpected reduction in IOP. The
left eyes of the rats were not treated.
Measurement of IOP and body weight
After the rats were anesthetized with isoflurane vaporized
with NARCOBIT-E (Natsume Seisakusho, Tokyo, Japan),
IOP was measured between 9 AM and 2 PM by applying
a rebound tonometer (Tonorab; TioLat, Helsinki, Finland)
to the center of the cornea. Body weight was measured
immediately after IOP measurement. This process was re-
peated every week.
Biochemical analysis of peripheral blood
The rats were deeply anesthetized with the intramuscu-
lar administration of a mixture of ketamine (500 mg/kg)
and xylazine (45 mg/kg). Blood samples were then gently
extracted from the heart after opening the thorax. The
blood samples were centrifuged and the supernatant was
collected as plasma, which was then sent to SRL, Inc.
(Tokyo, Japan) for biochemical analysis. A small amount
of whole blood was also collected in collection tubes con-
taining sodium fluoride to measure glycated hemoglobin
(HbA1c).
Western blotting
The anterior segment was collected by enucleating the
eye and dissecting and removing the posterior segment
(containing the retina, sclera, and choroid) and lens
from the rat eyes [18] and prepared for SDS-PAGE, as
previously described [19]. Ten micrograms of protein
per lane were loaded onto 10 % polyacrylamide gel
followed by electrophoresis and size separation of the
proteins. The proteins were then transferred to a PVDF
membrane, as previously described [20]. The membranes
were incubated with rabbit anti-CHOP (GADD153) anti-
body (sc-575, 1:1000, Santa Cruz Biotechnology, Dela-
ware, CA, USA) or rabbit anti-ATF4 (CREB2) antibody
(sc-200, 1:1000, Santa Cruz) as primary antibodies
overnight at 4 °C. After washing with Tween-PBS,
HRP-conjugated goat anti-rabbit antibody (Sigma) was in-
cubated as a secondary antibody at room temperature for
1 h. Immunoblots were visualized with ECL prime detec-
tion reagents (GE Healthcare, Piscataway, NJ, USA) and
immunosignal bands were captured with ChemiDoc XRS
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(Bio-Rad, Hercules, CA, USA). To detect beta-actin as an
internal control, the membrane was reblotted with Restore
Western Blot Stripping Buffer (Thermo Scientific, Hudson,
NH, USA). Mouse anti-beta-actin antibody was used as
the primary antibody. The expression of CHOP and ATF4
was induced by incubating RGC5 cells with 4 μg/ml of
tunicamycin (Wako Pure Chemical Industries, Osaka,
Japan) in a humidified atmosphere of 5 % CO2 and 95 %
air at 37 °C overnight.
Quantitative reverse-transcription PCR
Total RNA collected from the rat retinas was isolated
with an miRNeasy Mini Kit (Qiagen, Hilden, Germany),
according to the manufacturer’s instructions. Total RNA
(1 μg each) was used to generate first strand cDNA
using a SuperScript III First-Strand Synthesis SuperMix
for qRT-PCR (Life Technologies, Inc., MD, USA). Quan-
titative PCR (qPCR) was performed using a 7500 fast
real-time PCR system (Applied Biosystems, Foster City,
CA, USA) and amplified with TaqMan Fast Universal
PCR Master Mix (2X), No AmpErase UNG (Applied
Biosystems). The reaction was performed under the fol-
lowing condition: 95 °C for 20 s, 40 cycles of 95 °C for
3 s and 60 °C for 20 s. To amplify and detect the signal,
predesigned TaqMan probes (Life Technologies, Inc.)
were used, as follows: Thy1 (Rn00562048_m1), Nefh
(Rn00709325_m1), Pou4f1 (Rn01753495_m1), Pou4f2
(Rn01431271_g1), Pou4f3 (Rn00454761_g1), and Gapdh
(Rn01462662_g1). Each starting template was normalized
to Gapdh mRNA. Relative mRNA levels were calculated
with the delta-delta Ct method.
Results
Topical ocular dexamethasone decreased intraocular
pressure and body weight in the rats
The purpose of this study was to establish a rat model of
steroid-induced glaucoma by applying a protocol similar
to that used to elevate IOP in mice [18]. Therefore, we
initially planned to instill the dose-adjusted dexametha-
sone eye drops 3 times daily for the period of 6 weeks as
described in the mouse protocol [18].
However, after 1 week of topical ocular treatment with
0.1 % dexamethasone, we noted an unexpected, significant
decline in the body weight of the dexamethasone-treated
rats (358.3 ± 23.3 g; mean ± standard deviation) compared
to the saline-treated rats (410.8 ± 16.8 g; mean ± standard
deviation; P = 0.0004; Fig. 1). The body weight of the
steroid-treated rats continued to show a steady decline in
the following weeks, and had decreased to ~66.6 % of that
of the saline-treated group after treatment for 4 weeks.
Even more surprisingly, we observed that this decline in
body weight was accompanied by a reduction in IOP start-
ing after 2 weeks of treatment. IOP was significantly lower
(falling to ~76.3 % of that of the saline-treated rats) in the
steroid-treated eyes (11.3 ± 1.4 mmHg) than in the control
eyes (14.8 ± 2.4 mmHg; P = 0.0032; Fig. 2) after 3 weeks of
administration. In addition, IOP in the untreated contra-
lateral left eyes also decreased after topical dexamethasone
treatment in rats (Additional file 1: Figure S1), leading us
to speculate that the IOP reduction in the DEX-treated
rats was due to a systemic influence, not an effect specific
to the eyes. Similar results were obtained after 4 weeks of
steroid instillation. At this point, we decided to discon-
tinue the study as it was clear that the rats were respond-
ing very differently than mice, and that completing the
Fig. 1 Loss of body weight after topical dexamethasone treatment.
The body weight of vehicle-treated (0.9 % sodium chloride) and
DEX-treated (0.1 % dexamethasone) rats was measured weekly, after
IOP measurements. The graph shows the mean ± standard deviation
of the rats’ body weight (N = 12). ***P < 0.001, unpaired t-test
Fig. 2 IOP reduction after topical dexamethasone treatment. Topical
ocular vehicle or DEX was administered 3 times daily for up to
4 weeks. IOP measurements from vehicle-treated and 0.1 %
dexamethasone-treated rats are shown. Values represent the
mean ± standard deviatio of the mean (N = 12). *P < 0.05, **P < 0.01,
unpaired t-test
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initially planned 6 weeks of treatment would not bring us
closer to our goal of establishing a rat model of ocular
hypertension and steroid-induced glaucoma.
Discontinuing the experiment was also the most
appropriate response considering the ethical norms of our
institution’s guidelines for animal research.
Topical ocular dexamethasone increased plasma
cholesterol and alanine transaminase without affecting
blood glucose
In order to better understand the medical phenomenon
underlying the decline in body weight and the reduction
in IOP caused by the steroid eye drops, we collected
plasma from the rats after 4 weeks of treatment and ana-
lyzed its biochemical properties. The results showed that
cholesterol and alanine transaminase (ALT) levels were
dramatically higher (both by ~3.3-fold) in the steroid-
treated rats than the saline-treated rats (Table 1). On
the other hand, the creatinine level significantly de-
creased in the steroid-treated group. Interestingly, this
was not accompanied by an increase in short-term
(plasma glucose) or long-term (blood HbA1c) blood
glucose measurements.
RGC markers and ER stress markers were not altered by
topical ocular dexamethasone
After collecting the eyes at the 4-week time point, we
quantified the gene expression of Thy1, Nefh, Pou4f1,
Pou4f2 and Pou4f3, all regarded as constitutive RGC
markers, to assess damage to the RGCs after the topical
Table 1 Total cholesterol and ALT in blood samples increased
after topical dexamethasone treatment. Blood samples were
analyzed after 4 weeks of treatment. All data are expressed as
the mean ± standard deviation (N = 6)
Terms Unit Vehicle DEX p value
Albumin (g/dL) 4.15 ± 0.12 4.05 ± 0.36 0.5359
ALP (IU/L) 525.5 ± 74.9 656.8 ± 169 0.117
ALT (GPT) (IU/L) 57.0 ± 23.1 190.7 ± 169 0.0197
AST (GOT) (IU/L) 93.5 ± 23.4 164.7 ± 89.8 0.0897
Calcium (mg/dL) 10.3 ± 0.32 10.1 ± 0.35 0.29
Chloride (mEQ/L) 102.0 ± 1.91 101.0 ± 1.67 0.2487
Cholineesterase (IU/L) 6.83 ± 2.04 5.50 ± 0.55 0.1533
Creatinine (mg/dL) 0.26 ± 0.03 0.20 ± 0.04 0.0132
Free fatty acid (μEQ/L) 176.7 ± 80.0 382.7 ± 245.6 0.0793
Glucose (mg/dL) 169.7 ± 13.2 166.2 ± 57.9 0.888
HbA1c (NGSP) (%) 4.87 ± 0.37 5.55 ± 0.92 0.12234
Inorganic phosphorus (mg/dL) 7.57 ± 0.56 8.30 ± 1.67 0.331
Potassium (mEQ/L) 4.78 ± 0.50 4.82 ± 1.08 0.9466
Sodium (mEQ/L) 143.8 ± 0.98 145.2 ± 1.60 0.1129
Total cholesterol (mg/dL) 70.0 ± 16.8 230.5 ± 37.6 <0.0001
Total protein (g/dL) 6.23 ± 0.32 6.35 ± 0.37 0.5739
Triglyceride (mg/dL) 165.2 ± 63.3 208.2 ± 47.2 0.2119
Urea nitrogen (mg/dL) 18.62 ± 1.56 19.28 ± 2.42 0.583
γ – GTP (IU/L) <3 <3
ALP alkaline phosphatase, ALT, alanine transaminase, GPT glutamic pyruvic
transaminase, AST aspartate aminotransferase, GOT glutamic oxaloacetic
transaminase, HbA1c glycated hemoglobin, γ-GTP
gamma-glutamyl transpeptidase
Bold data represent the term that have significantly difference between
control and dex treatment
Fig. 3 a Gene expression of RGC markers in the rat retinas was
unaltered after topical dexamethasone treatment. The relative mRNA
level of RGC markers was compared in the eyes of rats treated with
0.1 % dexamethasone (DEX) or vehicle for 4 weeks (each N = 5). The
expression of the RGC markers was normalized to Gapdh. Values
represent the mean ± standard deviation. b The expression of ER
stress markers in the rat anterior segment was unaltered after topical
dexamethasone treatment. Topical dexamethasone did not elevate
the ER stress markers CHOP and ATF4 in the rats. Protein levels of
CHOP and ATF4 in anterior segment tissue (AST) were examined
with an immunoblot analysis in the rat eyes treated with saline
vehicle (Veh) or 0.1 % dexamethasone (DEX) for 4 weeks.
Tunicamycin (Tunic)-treated-RGC5 cells were used as a positive
control for ER stress induction. DMSO was used as a vehicle for the
tunicamycin treatment in the RGC5 cells. Beta-actin served as the
loading control (N = 3)
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administration of dexamethasone (Fig. 3a). We found no
significant difference in RGC marker expression between
the eyes treated with topical steroid and those
treated with saline. As the reduced expression of
RGC markers precedes the loss of the RGCs them-
selves, these results were consistent with the failure
to induce elevated IOP and the consequent RGC loss.
In addition, we found that there was no obvious loss
of the RGCs located in the GCL. Furthermore there
was no detectable loss of other types of retinal cells
nor were there any histological abnormalities (Additional
file 1: Figure S2). Previous studies that used mice showed
that the ER stress response was activated in the anterior
segment early in the disease process, particularly in the
trabecular meshwork, leading to IOP elevation [18]. To
determine if this also occurred in rats after topical ster-
oid treatment for 4 weeks, we tested for the induction of
ER stress by analyzing the protein expression of the rep-
resentative ER stress markers ATF4 and CHOP [21–23].
Both of these markers, previously shown to be elevated
in dexamethasone-treated mouse eyes, were not up-
regulated after topical steroid treatment in rats (Fig. 3b).
Discussion
In this study, we initially attempted to replicate, in rats,
a technique to induce IOP elevation that had been previ-
ously reported in mice [18]. However, to our surprise,
we found that topical ocular dexamethasone administra-
tion resulted in a paradoxical decrease in IOP.
This decrease in IOP was preceded by a rapid reduc-
tion in body weight that was not described in the ori-
ginal findings in mice [18]. Assuming that body weight
was indeed unaffected by dexamethasone treatment in
mice, this difference may explain the IOP decrease we
observed. The loss of body weight after corticosteroid
use in rats was unexpected as it is known that common
side effects of glucocorticoid in humans include gain of
weight. However, the development of stomach irritation
is also commonly observed, which could have led to the
loss of appetite and weight. Another possibility is the
taste alteration following corticosteroid use, which may
have also reduced their appetite and body weight. We
also observed increased cholesterol and ALT levels in
the rats following treatment, but it is relatively unlikely
that these biochemical parameters had a direct effect on
IOP. Elevated ALT and total cholesterol are consistent
with liver dysfunction as hepatocytes are involved in the
metabolism of these molecules. However, it is difficult
to link directly the liver dysfunction and the loss of
weight; the association remains unclear. Similarly, a re-
duced IOP is not a common findings in patients with
liver dysfuction, thus their relationship is also uncer-
tain. A possible explanation for the reduced IOP in-
cludes the reduction of orbital fat and orbital pressure
accompanied by the weight loss. Indeed, a recent re-
port has shown that cardiometabolic risk factors, in-
cluding total cholesterol, are associated with increased
IOP in Korean subjects [24]. High levels of total chol-
esterol did not induce a similar elevation in IOP in the
glucocorticoid-treated rats in our study, possibly due
to differences in species and the period of increased
total cholesterol. Additionally, elevated ALT in human
subjects has not been shown to have a convincing asso-
ciation with increased IOP or glaucoma.
Moreover, as dexamethasone has been reported to
increase mRNA and protein levels of ALT in mice [25],
it is possible that ALT might be similarly affected in
rats following treatment. In this case, the effect of
dexamethasone on ALT levels would not account for
the different IOP responses in the two different types
of rodent. Another notable difference between this
study and the previous work that used mice, which
may have affected the systemic side effects of dexa-
methasone we observed, was the relatively lower dose
given to the rats. Rats are 10 times heavier than mice,
but the dose was only increased 2.5-fold. Finally,
contradictory pharmacological responses in moder-
ately related species are not unprecedented. For ex-
ample, the intraperitoneal injection of dexamethasone
induces hepatocellular necrosis in rats [26], but not in
mice [25].
It is unclear why steroid treatment led to a decrease
in body weight. As steroid treatment can induce dia-
betes, which may result in a reduction of body weight,
we anticipated that blood glucose would be elevated as
the result of topical ocular dexamethasone. However, a
biochemical analysis of the blood samples showed that
this straightforward outcome did not occur. In fact,
only total cholesterol and ALT levels were elevated in
the rats treated with topical dexamethasone. Regardless
of the exact pathological mechanism, glucocorticoid
treatment has been shown to be associated with re-
duced body weight [27]. As this treatment strongly pro-
motes protein catabolism, it can also induce muscle
atrophy as a side effect [28]. This is believed to be medi-
ated by the sequential suppression of myostatin, the ac-
tivation of mTOR, and the induction of the FoxO
cascade, which results in promotion of autophagy of the
muscles [29–31].
Conclusions
In conclusion, topical ocular dexamethasone instillation
resulted in decreased IOP in rats, a reaction that was op-
posite to that previously observed in mice. As this was
accompanied by the loss of body weight and the eleva-
tion of plasma cholesterol and ALT, it appears that rats
are more sensitive than mice to systemic side effects
from ocular steroid treatment.
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Additional file
Additional file 1: Figure S1. IOP reduction in untreated left eye after
topical dexamethasone treatment in rat. Topical ocular vehicle or DEX
was administered 3 times daily for up to 4 weeks in the right eye. IOP
measurements of untreated contralateral left eye from vehicle-treated
and 0.1% dexamethasone-treated rats are shown. Values represent the
mean ± standard deviation (N = 12). *P < 0.05, ***P < 0.001, unpaired
t-test. Figure S2. No alteration of the retinal histology or loss of RGCs
observed following topical ocular treatment with dexamethasone in the
rats. Retinal histological sections were stained by H&E. GCL, ganglion cell
layer; IPL, inner plexiform layer; INL, inner nuclear layer; OPL, outer plexiform
layer; ONL, outer nuclear layer. Scale bars=50 μm. (DOCX 119 kb)
Abbreviations
ALT: Alanine transaminase; DEX: Dexamethasone; GCL: Ganglion cell layer;
HbA1c: Glycated hemoglobin; IOP: Intraocular pressure; qRT-PCR: Quantitative
reverse transcriptase polymerase chain reaction; RGCs: Retinal ganglion cells;
SDS-PAGE: Sodium dodecyl sulfate-poly- acrylamide gel electrophoresis.
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